Kuethmann A., Bezirkskrankenhaus Memmingen, Department of Psychiatry and Psychotherapy
Ogura, Y., Kitada, M., Xu, J., Monno, I
Users with certain genetic profiles may experience milder or more pronounced gastrointestinal effects, enabling your prescriber to adjust starting doses accordingly
Modulation of the effects of the cannabinoid agonist, ACPA, on spatial and non-spatial novelty detection in mice by dopamine D1 receptor drugs infused into the basolateral amygdala
According to CMS guidance, physicians who prescribe GLP-1 drugs under the Bridge must attest to the patient's clinical eligibility at the time therapy was first initiated even if that initial prescription was written before July 1, 2026
Questions For You Tap a prompt to share your answer we'll use it plus this page's context to start a tailored conversation